WEBINAR-Wednesday 12 April 2022- 5pm Central European Time
Depixus® is developing its MAGNA™ platform to unlock dramatic new insights into the largely unmined richness of the “dynamic genome” by detecting changes beyond the four-base sequences of DNA and RNA, paving the way to revolutionise molecular diagnostics and drug development. Dr Jimmy Ouellet, Chief Scientist will introduce the MAGNA™ platform which is based on […]
Read More
Clinical Epigenetics International Conference
Depixus® will be participating in Cambridge Healthtech Institute’s 12th Annual Circulating Tumor Cells and Liquid Biopsy Conference, San Diego, USA, from 21 to 22 February, 2022.
Read More
Depixus® raises EUR 30.6M (USD 35.4M) In Series A financing
16th December 2021
The financing will support development of a commercial instrument system based on the company’s proprietary and disruptive MAGNA™ technology.
Read More